207 related articles for article (PubMed ID: 19965692)
1. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia.
Cristóbal I; Blanco FJ; Garcia-Orti L; Marcotegui N; Vicente C; Rifon J; Novo FJ; Bandres E; Calasanz MJ; Bernabeu C; Odero MD
Blood; 2010 Jan; 115(3):615-25. PubMed ID: 19965692
[TBL] [Abstract][Full Text] [Related]
2. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
[TBL] [Abstract][Full Text] [Related]
3. Somatic SETBP1 mutations in myeloid malignancies.
Makishima H; Yoshida K; Nguyen N; Przychodzen B; Sanada M; Okuno Y; Ng KP; Gudmundsson KO; Vishwakarma BA; Jerez A; Gomez-Segui I; Takahashi M; Shiraishi Y; Nagata Y; Guinta K; Mori H; Sekeres MA; Chiba K; Tanaka H; Muramatsu H; Sakaguchi H; Paquette RL; McDevitt MA; Kojima S; Saunthararajah Y; Miyano S; Shih LY; Du Y; Ogawa S; Maciejewski JP
Nat Genet; 2013 Aug; 45(8):942-6. PubMed ID: 23832012
[TBL] [Abstract][Full Text] [Related]
4. SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia.
Albano F; Anelli L; Zagaria A; Coccaro N; Casieri P; Minervini A; Specchia G
J Hematol Oncol; 2012 Aug; 5():48. PubMed ID: 22873195
[TBL] [Abstract][Full Text] [Related]
5. Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.
Choi HW; Kim HR; Baek HJ; Kook H; Cho D; Shin JH; Suh SP; Ryang DW; Shin MG
Ann Lab Med; 2015 Jan; 35(1):118-22. PubMed ID: 25553291
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
Cristóbal I; Garcia-Orti L; Cirauqui C; Cortes-Lavaud X; García-Sánchez MA; Calasanz MJ; Odero MD
Haematologica; 2012 Apr; 97(4):543-50. PubMed ID: 22133779
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.
Torrejón B; Cristóbal I; Caramés C; Prieto-Potín I; Chamizo C; Santos A; Sanz-Alvarez M; Serna-Blasco R; Luque M; Madoz-Gúrpide J; Rojo F; García-Foncillas J
World J Surg; 2018 Nov; 42(11):3771-3778. PubMed ID: 29796729
[TBL] [Abstract][Full Text] [Related]
8. Somatic SETBP1 mutations in myeloid neoplasms.
Makishima H
Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248
[TBL] [Abstract][Full Text] [Related]
9. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
[TBL] [Abstract][Full Text] [Related]
10. TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia.
Wang N; Guo D; Zhao YY; Dong CY; Liu XY; Yang BX; Wang SW; Wang L; Liu QG; Ren Q; Lin YM; Ma XT
Oncotarget; 2015 Aug; 6(25):20977-92. PubMed ID: 26023795
[TBL] [Abstract][Full Text] [Related]
11. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
[TBL] [Abstract][Full Text] [Related]
12. Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10.
Oakley K; Han Y; Vishwakarma BA; Chu S; Bhatia R; Gudmundsson KO; Keller J; Chen X; Vasko V; Jenkins NA; Copeland NG; Du Y
Blood; 2012 Jun; 119(25):6099-108. PubMed ID: 22566606
[TBL] [Abstract][Full Text] [Related]
13. Myb expression is critical for myeloid leukemia development induced by Setbp1 activation.
Nguyen N; Vishwakarma BA; Oakley K; Han Y; Przychodzen B; Maciejewski JP; Du Y
Oncotarget; 2016 Dec; 7(52):86300-86312. PubMed ID: 27863435
[TBL] [Abstract][Full Text] [Related]
14. Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development.
Vishwakarma BA; Nguyen N; Makishima H; Hosono N; Gudmundsson KO; Negi V; Oakley K; Han Y; Przychodzen B; Maciejewski JP; Du Y
Leukemia; 2016 Jan; 30(1):200-8. PubMed ID: 26205084
[TBL] [Abstract][Full Text] [Related]
15. Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia.
Rawat VP; Cusan M; Deshpande A; Hiddemann W; Quintanilla-Martinez L; Humphries RK; Bohlander SK; Feuring-Buske M; Buske C
Proc Natl Acad Sci U S A; 2004 Jan; 101(3):817-22. PubMed ID: 14718672
[TBL] [Abstract][Full Text] [Related]
16. SETBP1 is dispensable for normal and malignant hematopoiesis.
Tanaka A; Nishimura K; Saika W; Kon A; Koike Y; Tatsumi H; Takeda J; Nomura M; Zang W; Nakayama M; Matsuda M; Yamazaki H; Fukumoto M; Ito H; Hayashi Y; Kitamura T; Kawamoto H; Takaori-Kondo A; Koseki H; Ogawa S; Inoue D
Leukemia; 2023 Sep; 37(9):1802-1811. PubMed ID: 37464069
[TBL] [Abstract][Full Text] [Related]
17. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
Cristóbal I; Garcia-Orti L; Cirauqui C; Alonso MM; Calasanz MJ; Odero MD
Leukemia; 2011 Apr; 25(4):606-14. PubMed ID: 21233840
[TBL] [Abstract][Full Text] [Related]
18. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
19. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
Balgobind BV; Lugthart S; Hollink IH; Arentsen-Peters ST; van Wering ER; de Graaf SS; Reinhardt D; Creutzig U; Kaspers GJ; de Bont ES; Stary J; Trka J; Zimmermann M; Beverloo HB; Pieters R; Delwel R; Zwaan CM; van den Heuvel-Eibrink MM
Leukemia; 2010 May; 24(5):942-9. PubMed ID: 20357826
[TBL] [Abstract][Full Text] [Related]
20. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R
Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
